Literature DB >> 30082430

CD40L/IL-4-stimulated CLL demonstrates variation in translational regulation of DNA damage response genes including ATM.

Larissa Lezina1,2, Ruth V Spriggs3, Daniel Beck1,2, Carolyn Jones3, Kate M Dudek3, Aleksandra Bzura1, George D D Jones1, Graham Packham4, Anne E Willis3, Simon D Wagner1.   

Abstract

CD40L/interleukin-4 (IL-4) stimulation occurs in vivo in the tumor microenvironment and induces global translation to varying degrees in individuals with chronic lymphocytic leukemia (CLL) in vitro. However, the implications of CD40L/IL-4 for the translation of specific genes is not known. To determine the most highly translationally regulated genes in response to CD40L/IL-4, we carried out ribosome profiling, a next-generation sequencing method. Significant differences in the translational efficiency of DNA damage response genes, specifically ataxia-telangiectasia-mutated kinase (ATM) and the MRE11/RAD50/NBN (MRN) complex, were observed between patients, suggesting different patterns of translational regulation. We confirmed associations between CD40L/IL-4 response and baseline ATM levels, induction of ATM, and phosphorylation of the ATM targets, p53 and H2AX. X-irradiation was used to demonstrate that CD40L/IL-4 stimulation tended to improve DNA damage repair. Baseline ATM levels, independent of the presence of 11q deletion, correlated with overall survival (OS). Overall, we suggest that there are individual differences in translation of specific genes, including ATM, in response to CD40L/IL-4 and that these interpatient differences might be clinically important.
© 2018 by The American Society of Hematology.

Entities:  

Mesh:

Substances:

Year:  2018        PMID: 30082430      PMCID: PMC6093746          DOI: 10.1182/bloodadvances.2017015560

Source DB:  PubMed          Journal:  Blood Adv        ISSN: 2473-9529


  45 in total

1.  Gene set enrichment analysis: a knowledge-based approach for interpreting genome-wide expression profiles.

Authors:  Aravind Subramanian; Pablo Tamayo; Vamsi K Mootha; Sayan Mukherjee; Benjamin L Ebert; Michael A Gillette; Amanda Paulovich; Scott L Pomeroy; Todd R Golub; Eric S Lander; Jill P Mesirov
Journal:  Proc Natl Acad Sci U S A       Date:  2005-09-30       Impact factor: 11.205

2.  Functional interaction of H2AX, NBS1, and p53 in ATM-dependent DNA damage responses and tumor suppression.

Authors:  Jian Kang; David Ferguson; Hoseok Song; Craig Bassing; Mark Eckersdorff; Frederick W Alt; Yang Xu
Journal:  Mol Cell Biol       Date:  2005-01       Impact factor: 4.272

3.  The lymph node microenvironment promotes B-cell receptor signaling, NF-kappaB activation, and tumor proliferation in chronic lymphocytic leukemia.

Authors:  Yair Herishanu; Patricia Pérez-Galán; Delong Liu; Angélique Biancotto; Stefania Pittaluga; Berengere Vire; Federica Gibellini; Ndegwa Njuguna; Elinor Lee; Lawrence Stennett; Nalini Raghavachari; Poching Liu; J Philip McCoy; Mark Raffeld; Maryalice Stetler-Stevenson; Constance Yuan; Richard Sherry; Diane C Arthur; Irina Maric; Therese White; Gerald E Marti; Peter Munson; Wyndham H Wilson; Adrian Wiestner
Journal:  Blood       Date:  2010-10-12       Impact factor: 22.113

4.  Aggressive chronic lymphocytic leukemia with elevated genomic complexity is associated with multiple gene defects in the response to DNA double-strand breaks.

Authors:  Peter Ouillette; Samuel Fossum; Brian Parkin; Li Ding; Paula Bockenstedt; Ammar Al-Zoubi; Kerby Shedden; Sami N Malek
Journal:  Clin Cancer Res       Date:  2010-01-19       Impact factor: 12.531

5.  Responsiveness of chronic lymphocytic leukemia B cells activated via surface Igs or CD40 to B-cell tropic factors.

Authors:  A C Fluckiger; J F Rossi; A Bussel; P Bryon; J Banchereau; T Defrance
Journal:  Blood       Date:  1992-12-15       Impact factor: 22.113

6.  The Myc-evoked DNA damage response accounts for treatment resistance in primary lymphomas in vivo.

Authors:  Maurice Reimann; Christoph Loddenkemper; Cornelia Rudolph; Ines Schildhauer; Bianca Teichmann; Harald Stein; Brigitte Schlegelberger; Bernd Dörken; Clemens A Schmitt
Journal:  Blood       Date:  2007-06-11       Impact factor: 22.113

7.  Dissecting eIF4E action in tumorigenesis.

Authors:  Hans-Guido Wendel; Ricardo L A Silva; Abba Malina; John R Mills; Hong Zhu; Takeshi Ueda; Rie Watanabe-Fukunaga; Rikiro Fukunaga; Julie Teruya-Feldstein; Jerry Pelletier; Scott W Lowe
Journal:  Genes Dev       Date:  2007-11-30       Impact factor: 11.361

8.  Genome-wide analysis in vivo of translation with nucleotide resolution using ribosome profiling.

Authors:  Nicholas T Ingolia; Sina Ghaemmaghami; John R S Newman; Jonathan S Weissman
Journal:  Science       Date:  2009-02-12       Impact factor: 47.728

9.  The awesome power of ribosome profiling.

Authors:  Richard Jackson; Nancy Standart
Journal:  RNA       Date:  2015-04       Impact factor: 4.942

10.  ATR inhibition induces synthetic lethality and overcomes chemoresistance in TP53- or ATM-defective chronic lymphocytic leukemia cells.

Authors:  Marwan Kwok; Nicholas Davies; Angelo Agathanggelou; Edward Smith; Ceri Oldreive; Eva Petermann; Grant Stewart; Jeff Brown; Alan Lau; Guy Pratt; Helen Parry; Malcolm Taylor; Paul Moss; Peter Hillmen; Tatjana Stankovic
Journal:  Blood       Date:  2015-11-12       Impact factor: 22.113

View more
  6 in total

1.  Mechanism for IL-15-Driven B Cell Chronic Lymphocytic Leukemia Cycling: Roles for AKT and STAT5 in Modulating Cyclin D2 and DNA Damage Response Proteins.

Authors:  Rashmi Gupta; Wentian Li; Xiao J Yan; Jacqueline Barrientos; Jonathan E Kolitz; Steven L Allen; Kanti Rai; Nicholas Chiorazzi; Patricia K A Mongini
Journal:  J Immunol       Date:  2019-04-15       Impact factor: 5.422

2.  Transcriptional Modulation by Idelalisib Synergizes with Bendamustine in Chronic Lymphocytic Leukemia.

Authors:  Sara E F Kost; Ali Saleh; Edgard M Mejia; Marina Mostafizar; Eric D J Bouchard; Versha Banerji; Aaron J Marshall; Spencer B Gibson; James B Johnston; Sachin Katyal
Journal:  Cancers (Basel)       Date:  2019-10-09       Impact factor: 6.639

3.  Elucidation of Focal Adhesion Kinase as a Modulator of Migration and Invasion and as a Potential Therapeutic Target in Chronic Lymphocytic Leukemia.

Authors:  Thomas A Burley; Andrew Hesketh; Giselda Bucca; Emma Kennedy; Eleni E Ladikou; Benjamin P Towler; Simon Mitchell; Colin P Smith; Christopher Fegan; Rosalynd Johnston; Andrea Pepper; Chris Pepper
Journal:  Cancers (Basel)       Date:  2022-03-22       Impact factor: 6.575

Review 4.  Regulating tumor suppressor genes: post-translational modifications.

Authors:  Ling Chen; Shuang Liu; Yongguang Tao
Journal:  Signal Transduct Target Ther       Date:  2020-06-10

5.  Targeted inhibition of mRNA translation initiation factors as a novel therapeutic strategy for mature B-cell neoplasms.

Authors:  Joe Taylor; Alison M Yeomans; Graham Packham
Journal:  Explor Target Antitumor Ther       Date:  2020-02-29

6.  miR-29 modulates CD40 signaling in chronic lymphocytic leukemia by targeting TRAF4: an axis affected by BCR inhibitors.

Authors:  Sonali Sharma; Gabriela Mladonicka Pavlasova; Vaclav Seda; Katerina Amruz Cerna; Eva Vojackova; Daniel Filip; Laura Ondrisova; Veronika Sandova; Lenka Kostalova; Pedro F Zeni; Marek Borsky; Jan Oppelt; Kvetoslava Liskova; Leos Kren; Andrea Janikova; Sarka Pospisilova; Stacey M Fernandes; Medhat Shehata; Laura Z Rassenti; Ulrich Jaeger; Michael Doubek; Matthew S Davids; Jennifer R Brown; Jiri Mayer; Thomas J Kipps; Marek Mraz
Journal:  Blood       Date:  2021-05-06       Impact factor: 22.113

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.